Related Experiment Video
Updated: Nov 25, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.2K
Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy
Geeta S Bhagwat1, Rajani B Athawale2, Rajeev P Gude3
1H. K. College of Pharmacy, Mumbai, India.
Frontiers in Pharmacology
|December 17, 2020
Summary
This study developed transferrin-conjugated solid lipid nanoparticles (SLNs) for targeted delivery of tamoxifen citrate, a breast cancer drug. These novel nanoparticles show enhanced efficacy and reduced toxicity for improved breast cancer treatment.
Area of Science:
- Nanotechnology
- Pharmacology
- Oncology
Background:
- Breast cancer treatment often involves surgery, chemotherapy, radiation, and hormonal therapy.
- Tamoxifen citrate is a key hormonal therapy due to its selective estrogen receptor modulation, but it causes uterine toxicity and side effects.
- High doses of tamoxifen citrate can lead to toxicity in vital organs like the liver, kidney, and uterus.
Purpose of the Study:
- To develop transferrin-conjugated solid lipid nanoparticles (SLNs) for enhanced active targeting of tamoxifen citrate in breast cancer.
- To evaluate the physicochemical properties and in vitro performance of the developed tamoxifen citrate-loaded SLNs.
- To assess the cytotoxicity and cellular uptake of the novel nanocarrier system in human breast cancer cells.
Main Methods:
- Preparation and characterization of transferrin-conjugated solid lipid nanoparticles (SLNs) loaded with tamoxifen citrate.
- Evaluation of particle size, surface charge, surface morphology, and in vitro dissolution profiles.
- In vitro cytotoxicity assays on human breast cancer MCF-7 cells.
- Cell uptake and flow cytometry studies to confirm cellular internalization.
Main Results:
- Transferrin-conjugated SLNs were successfully prepared, showing favorable physicochemical properties.
- The developed SLN formulations exhibited significantly enhanced cytotoxicity against MCF-7 cells compared to pure tamoxifen citrate solution in a dose- and time-dependent manner.
- Cell uptake studies confirmed the effective internalization of the transferrin-engineered nanoparticles by breast cancer cells.
Conclusions:
- Transferrin-conjugated SLNs represent a promising nanocarrier system for targeted delivery of tamoxifen citrate in breast cancer therapy.
- This approach can enhance the therapeutic efficacy of nanomedicines while potentially mitigating systemic toxicity.
- Engineered nanocarriers hold potential for improving breast cancer treatment outcomes.
